The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Starboard Value has asked Pfizer to set up a special committee to investigate allegations that two of its former senior executives were forced to publicly declare support for CEO Albert Bourla, the hedge fund said on Thursday.
Pfizer stock skidded Thursday after former executives Ian Read and Frank D'Amelio sided with the drugmaker over activist investor Starboard.
Activist Starboard Value accused Pfizer of threatening litigation against two renegade former executives that initially were supportive of the investor's turnaround campaign at the pharmaceutical giant. Starboard's Jeff Smith called on the company to assemble a special committee to investigate the matter, describing it as "flagrantly unethical.
Pfizer Inc.'s stock dipped early Thursday, after two of its former executives said they would not support an effort by activist shareholder Starboard Value to orchestrate a turnaround.
Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of advanced prostate cancer in a late-stage study.
Both of these stocks should have plenty of room to run.
Pfizer's former CEO and Chair Ian Read and ex-CFO Frank D'Amelio said in a statement that they will not be involved with activist investor Starboard Value, which wants the U.S. drug giant to make changes to turn its performance around.
Two former Pfizer executives who were previously linked to activist investor Starboard Value's campaign at the struggling drugmaker said they would step back from the push late Wednesday evening. Former CEO Ian Read and ex-CFO Frank D'Amelio voiced their full support for current CEO Albert Bourla and the management team.
The sharp, sudden entry of an activist investor is raising hopes that change might come to the company.
Pfizer (PFE, Financial) experienced a 2.3% increase, reaching $29.85. The rise follows news that Pfizer's CEO plans to meet next week with key leaders from activist investor Starboard Value.
The story of activist fund Starboard Value taking a $1 billion position in Pfizer is grabbing headlines the last few days. However, no good new solutions are being offered, at least according to the stories and articles that have surfaced since the stake was first mentioned. Additional cost cutting, more share repurchases, or management and board changes are unlikely to make a change for the better at Pfizer.